Blockchain Registration Transaction Record
SureNano Science Targets Obesity Market with Novel GEP-44 Peptide
SureNano Science Ltd. (CSE:SURE) (OTCQB:SURNF) advances GEP-44 peptide for obesity, showing preclinical weight loss and glucose control. A potential non-injectable GLP-1 therapy.
This news matters because obesity and metabolic diseases are global health crises, and current GLP-1 therapies like Ozempic® are blockbusters but require injections. SureNano's GEP-44 peptide could offer a non-injectable alternative with better tolerability, potentially expanding access to millions of patients. If successful, it could disrupt the pharmaceutical market and provide new treatment options for those struggling with weight management and metabolic disorders.
| Blockchain | Details |
|---|---|
| Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
| Transaction ID | 0x949dce708d394bf66f9b697f23b8cef188b21fd540f2d3bed18d5fb602c35321 |
| Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
| Chain | polygon-main |
| NewsRamp Digital Fingerprint | swimZLZq-20481fe4adbc9547f90bef80b06b25e6 |